The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study

#4035

Introduction: Surufatinib (a small-molecule inhibitor of VEGFR1-3, FGFR1, and CSF-1R) has exhibited encouraging antitumor activity for the treatment of advanced neuroendocrine tumors (including NET and NEC) in multiple registration studies.

Aim(s): Here, we report the preliminary results of advanced neuroendocrine tumors of an ongoing, multicenter, real-world study of surufatinib with multidisciplinary collaborative diagnosis and treatment (MDT).

Materials and methods: In this multicenter, single-arm real-world study, adults (age: 18 to 80) with NET or NEC were eligible and received surufatinib (300mg orally, qd) with MDT. The primary endpoint was progression-free survival (PFS) per RECIST 1.1.

Conference:

Presenting Author: Jiang L

Authors: Jiang L, Chuntao W, Beiyuan H, Tao C, Haitao G,

Keywords: neuroendocrine tumor, real-world study, surufatinib,